Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 08 2019
Historique:
received: 17 01 2019
accepted: 01 08 2019
entrez: 14 8 2019
pubmed: 14 8 2019
medline: 27 10 2020
Statut: epublish

Résumé

Interferon (IFN)-γ is the major mediator of anti-tumor immune responses; nevertheless, cancer cells use intrigue strategies to alter IFN-γ signaling and avoid elimination. Understanding the immune regulatory mechanisms employed by acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cells upon exposure to IFN-γ is critical for development of immunotherapy and checkpoint blockade therapy approaches. This study aims to explore the influence of myeloid maturation on IFN-γ-induced PD-L1 and PD-L2 expression and on pro-leukemogenic transcription factor STAT3 signaling in AML and MDS. Stimulation of myeloid blasts' maturation by all-trans retinoic acid (ATRA) or 1α,25-dihydroxyvitamin D3 (vitamin D) increased the CD11b

Identifiants

pubmed: 31406210
doi: 10.1038/s41598-019-48256-4
pii: 10.1038/s41598-019-48256-4
pmc: PMC6691003
doi:

Substances chimiques

ARHGEF3 protein, human 0
B7-H1 Antigen 0
CD11b Antigen 0
CD274 protein, human 0
ITGAM protein, human 0
PDCD1LG2 protein, human 0
Programmed Cell Death 1 Ligand 2 Protein 0
Rho Guanine Nucleotide Exchange Factors 0
Tretinoin 5688UTC01R
Interferon-gamma 82115-62-6
Calcitriol FXC9231JVH

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11697

Références

Proc Natl Acad Sci U S A. 1981 Aug;78(8):4990-4
pubmed: 6946446
Blood. 2009 Dec 10;114(25):5126-35
pubmed: 19797519
Haematologica. 1998 Dec;83(12):1104-15
pubmed: 9949628
Ann Hematol. 2014 Sep;93(9):1483-9
pubmed: 24782118
J Clin Invest. 2018 Feb 1;128(2):580-588
pubmed: 29337303
Am J Hematol. 2006 Apr;81(4):227-35
pubmed: 16550517
J Clin Med. 2016 Mar 05;5(3):
pubmed: 26959069
Cancer Res. 2006 Sep 15;66(18):9299-307
pubmed: 16982775
Blood. 2012 Sep 6;120(10):2076-86
pubmed: 22753872
Blood. 2010 Aug 19;116(7):1124-31
pubmed: 20472834
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7
pubmed: 19088198
J Biol Chem. 2004 Oct 1;279(40):41679-85
pubmed: 15284232
Blood. 2002 Jan 1;99(1):252-7
pubmed: 11756179
Hum Gene Ther. 2012 Oct;23(10):1090-100
pubmed: 22779406
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Cancer Res. 2008 Dec 15;68(24):10121-7
pubmed: 19074878
Blood. 2011 May 26;117(21):5701-9
pubmed: 21447830
Mol Immunol. 2015 Dec;68(2 Pt C):692-8
pubmed: 26563945
J Virol. 1998 Nov;72(11):8463-71
pubmed: 9765382
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Blood. 2014 Oct 30;124(18):2793-803
pubmed: 25237199
J Biol Chem. 2006 May 19;281(20):14111-8
pubmed: 16571725
J Leukoc Biol. 1999 Mar;65(3):391-6
pubmed: 10080544
Trends Immunol. 2017 Jul;38(7):513-525
pubmed: 28511816
Immunotherapy. 2011 Jan;3(1):77-96
pubmed: 21174559
Sci Rep. 2014 Jan 16;4:3718
pubmed: 24430195
Immunology. 2016 Dec;149(4):460-471
pubmed: 27565576
Immunity. 2009 Oct 16;31(4):539-50
pubmed: 19833085
Chem Biol. 2006 Nov;13(11):1235-42
pubmed: 17114005
Eur J Immunol. 2011 Feb;41(2):413-24
pubmed: 21268011
J Immunol. 2005 Sep 15;175(6):3637-47
pubmed: 16148108
JAKSTAT. 2012 Apr 1;1(2):65-72
pubmed: 24058752
Blood. 2003 Jan 1;101(1):143-50
pubmed: 12393446
Expert Rev Hematol. 2015 Feb;8(1):29-41
pubmed: 25374305
Annu Rev Med. 2016;67:59-72
pubmed: 26473413
Nat Med. 2018 Dec;24(12):1877-1886
pubmed: 30374200
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Ann Hematol. 2017 Sep;96(9):1441-1448
pubmed: 28643044
J Immunother Cancer. 2013 Aug 27;1(13):
pubmed: 24353898
Expert Rev Hematol. 2018 May;11(5):373-389
pubmed: 29589969
Eur J Immunol. 2013 Mar;43(3):747-57
pubmed: 23175469
RNA. 2003 Apr;9(4):493-501
pubmed: 12649500
Cytokine Growth Factor Rev. 2016 Oct;31:73-81
pubmed: 27502919
PLoS One. 2015 Aug 26;10(8):e0135981
pubmed: 26309131
Mol Cancer Ther. 2010 Mar;9(3):742-50
pubmed: 20197401
Eur J Haematol. 2001 Aug;67(2):63-71
pubmed: 11722592
Cancer Immunol Immunother. 2010 Dec;59(12):1839-49
pubmed: 20814675
Immunobiology. 2018 Mar;223(3):342-347
pubmed: 29092744
Eur J Immunol. 2013 Mar;43(3):576-9
pubmed: 23381914

Auteurs

Digdem Yoyen-Ermis (D)

Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Lokman Hekim University, Faculty of Medicine, Department of Medical Biology, Ankara, Turkey.

Gurcan Tunali (G)

Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Ece Tavukcuoglu (E)

Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Utku Horzum (U)

Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Didem Ozkazanc (D)

Nanotechnology Research and Application Center, Sabanci University, Istanbul, Turkey.

Tolga Sutlu (T)

Nanotechnology Research and Application Center, Sabanci University, Istanbul, Turkey.

Yahya Buyukasik (Y)

Department of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Gunes Esendagli (G)

Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. gunes.esendagli@lycos.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH